Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Mesoblast named global technology leader in cell therapy industry

Mesoblast
Posted on: 11 Dec 17

New York, USA, and Melbourne, Australia: Mesoblast Limited has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry.

Mesoblast is a biopharma company specializing in cell therapies. It has used its proprietary technology platform to establish one of the industry’s most clinically advanced and diverse portfolio of cell-based product candidates. It currently has three cell therapy product candidates in Phase 3 clinical trials, in acute Graft versus Host Disease, chronic heart failure, and chronic lower back pain caused by disc degeneration. The Company expects to report primary endpoint results from its Phase 3 trial in pediatric acute Graft versus Host Disease in Q1 2018.

Frost & Sullivan Analyst and Industry Manager, Transformational Health, Sanjeev Kumar, said: "Mesoblast is an international industry leader due to its cutting edge mesenchymal lineage cell technology platform, deep intellectual property portfolio, late-phase clinical assets, and industrialized manufacturing capabilities."

Mesoblast Chief Executive Silviu Itescu welcomed the award, stating: “We are honored to be the first company named by Frost & Sullivan as the Global Technology Leader in the Cell Therapy Industry. This award recognizes the efforts of the whole Mesoblast team and our investors whose support has been instrumental in the development of our innovative cell therapy product candidates.”

Frost & Sullivan’s Best Practices Awards recognize companies that lead the development and successful introduction of high-tech solutions to customers’ most pressing needs, altering the industry or business landscape in the process. Its industry analyst team benchmarks market participants and measures their performance through independent, primary interviews, and secondary industry research to evaluate and identify best practices.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. www.frost.com

About Mesoblast

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of latestage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

 

FOR MEDIA INFORMATION:

On behalf of Mesoblast
Simon Vane Percy
Vane Percy & Roberts
(T) +44 (0) 1737 821890
(e) simon@vanepercy.com

For further information, please contact:

Julie Meldrum Corporate Communications T: +61 3 9639 6036 E: julie.meldrum@mesoblast.com

Schond Greenway Investor Relations T: +1 212 880 2060 E: schond.greenway@mesoblast.com

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 11/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.